# A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

> **NCT07184385** · PHASE3 · NOT_YET_RECRUITING · sponsor: **StemCyte, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Long COVID
- Post-COVID-19 Condition
- Post-COVID Syndrome
- Post-COVID Condition

## Interventions

- **BIOLOGICAL:** REGENECYTE
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07184385
- **Lead sponsor:** StemCyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184385, "A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07184385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*